The Agenda includes the following Sickle Cell Agents:
Droxia (hydroxyurea) Bristol Myers Squibb
Endari by Emmaus Medical
Oxbryta by Global Blood Therapeutics (GBT)
Siklos (hydroxyurea) by Medunik
Adakveo by Novartis
Stay in the Know
Sign up for our newsletter!
